Actor Menggie Cobarrubias passes away

0

MANILA, Philippines — Veteran actor Menggie Cobarrubias on Wednesday night posted a simple “Good bye” on his Facebook account. The following morning, his wife Gina Jorge Cobarrubias confirmed that the actor had passed away.

Good bye

Posted by Domingo Cobarrubias on Wednesday, March 25, 2020

“Goodbye my love. Thank you for the 30 wonderful years. I love you,” she said on Facebook Thursday. “Dear God please give me the strength to be able to face this very difficult moment of my life.”

Goodbye my love. Thank you for the 30 wonderful years. I love you. Dear God please give me the strength to be able to face this very difficult moment of my life.

Posted by Gina Jorge Cobarrubias on Wednesday, March 25, 2020

His death was also announced by a relative, Patricia Prudon, who said in a now-deleted post that he died from pneumonia complications. She said it had yet to be confirmed if he had contracted the coronavirus disease (COVID-19).

According to a Facebook post of actress Lui Quiambao Manansala on Wednesday night, Cobarrubias was in critical condition and that they were waiting for the results of a coronavirus test he took on Tuesday.

Pls pray for Domingo Cobarrubias, or Menggie. He is critical. Waiting for tuesday’s Covid 19 test result.

Posted by Lui Quiambao Manansala on Wednesday, March 25, 2020

Cobarrubias starred in ABS-CBN teleseryes “Make It With You” and “The Killer Bride,” as well as in the 2018 award-winning Cinemalaya film “Kung Paano Hinihintay ang Dapithapon.”


For more news about the novel coronavirus click here.

What you need to know about Coronavirus.

For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

Read Next

EDITORS’ PICK

MOST READ

Don’t miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

For feedback, complaints, or inquiries, contact us.



Source

Comments
Loading...